

## Rekap Korespondensi dengan Journal of Pakistan Associations of Dermatologists

No	Tanggal	Uraian	Halaman	Ket
1	27 July 2022	Submit Paper to JPAD	<b>Page 1</b>	
2	29 July 2022	Paper has been underreview	<b>Page 2</b>	
3	20 September 2022	Paper has been formally accepted as regular paper (JPAD) Confirmation about the paper's schedule to JPAD Vol 32 Issue 4 of 2022 (published in December 2022)	<b>Page 3-5</b>	
4	8 December 2022	Paper published online (JPAD Vol 32 Issue 4, October-December 2022)	<b>Page 6-9</b>	



Submissions

2029 / **Murtiastutik et al.** / Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS





Library

Workflow **Publication**

**Submission** Review Copyediting Production

Submission Files

Search

▶  5624-1	dwimurtiastutik, Main Document.docx	July 27, 2022	Article Text
▶  5625-1	dwimurtiastutik, Source Texts.docx	July 27, 2022	Source Texts
▶  5626-1	dwimurtiastutik, Data Set.docx	July 27, 2022	Data Set
▶  5627-1	dwimurtiastutik, Research Instrument.docx	July 27, 2022	Research Instrument

Download All Files

PAGE 1

Round 1

**Round 1 Status**

Submission accepted.

**Reviewer's Attachments**

[Search](#)

No Files

**Revisions**

[Search](#)

[Upload File](#)

No Files

**Review Discussions**

[Add discussion](#)

Name	From	Last Reply	Replies	Closed
<a href="#">[JPAD Manuscript status]</a>	ihussain2022- 07-29 01:32 AM	-	0	<input type="checkbox"/>



Submissions

2029 / Murtiastutik et al. / Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS

Library

Workflow Publication

Submission Review Copyediting Production

Production Discussions

Add discussion

Name	From	Last Reply	Replies	Closed
<a href="#">[Manuscript status-acceptance]</a>	ihussain2022-09-20 11:56 AM	dwimurtiastutik2022-09-20 11:34 PM	1	<input type="checkbox"/>

PAGE 3



### Participants

Dr. Zahida Rani (ihussain)

Dr. Dwi Murtiastutik (dwimurtiastutik)

### Messages

Note	From
Dear author This is for your kind information that your manuscript has been accepted for publication and the tentative plan to publish it is in JPAD Vol 32(4) Oct-Dec, 2022 issue. We shall inform you through email once it is uploaded on the official website and will send you a hard copy of the issue through courier after its printing/publication. Regards Dr. Zahida Rani Editor, JPAD	ihussain2022-09-20 11:56 AM
▶ Dear Dr. Zahida Rani Editor, JPAD We would like to thank you for the acceptance of our manuscript ID#2029: "Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS" in JPAD Vol 32(4) Oct-Dec, 2022 issue. Thank you for the kind coordination and for constructive suggestions. Warm regards, Dwi Murtiastutik	dwimurtiastutik2022-09-20 11:34 PM

Add Message

- Re: [JPAD Ack#2029]Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS

Yahoo/Email M... ★



● **JPAD Journal** <jpad.journal@gmail.com>

Kepada: Yahoo Mail, Ijaz Hussain, Zahida Rani



Sel, 20 Sep 2022 jam 22.56 ★

Dear author

This is for your kind information that your manuscript titled ID#2029: Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS has been accepted for publication and the tentative plan to publish it is in JPAD Vol 32(4) Oct-Dec, 2022 issue. We shall inform you through email once it is uploaded on the official website and will send you a hard copy of the issue through courier after its printing/publication.

Regards

Dr. Zahida Rani  
Editor, JPAD



On Fri, 29 Jul 2022 at 10:32, JPAD Journal <jpad.journal@gmail.com> wrote:

Dear author.

Thank you very much for your following submission to JPAD.

ID#2029 : Basil Leaf Extract and Eugenol against Isolates of Candida sp. Causing Oral Candidiasis in HIV/AIDS

It will go through review/ peer review process. We Shall intimate you after 5-6 weeks regarding further progress of your submission.

Please do mention your article ID#2029 for future reference.

Regards

Dr. Zahida Rani  
Editor, JPAD

## Original Article

# Basil leaf extract and eugenol against isolates of *Candida* sp. causing oral candidiasis in HIV/AIDS

Dwi Murtiastutik<sup>1</sup>, Emma Hidayati Sasmito<sup>1</sup>, Afif Nurul Hidayati<sup>1,2</sup>, Rahmadewi<sup>1</sup>, Sawitri<sup>1</sup>, Budi Utomo<sup>3</sup>, Sudjarwo<sup>4</sup>, Pepy Dwi Endraswari<sup>5,6</sup>, Diah Mira Indramaya<sup>1</sup>

<sup>1</sup>Department of Dermatology and Venereology, Dr. Soetomo General Academic Teaching Hospital, Surabaya, Indonesia.

<sup>2</sup>Department of Dermatology and Venereology, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.

<sup>3</sup>Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

<sup>4</sup>Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.

<sup>5</sup>Department of Clinical Microbiology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Teaching Hospital, Surabaya, Indonesia.

<sup>6</sup>Department of Clinical Microbiology, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.

## Abstract

**Background** Oral candidiasis is an opportunistic infection of the oral mucosa caused by *Candida* sp., frequently found in HIV/AIDS patients. Basil leaf extract (*Ocimum sanctum* Linn.), which contains eugenol, a compound believed to inhibit the growth of *Candida* sp.

**Objective** To evaluate the antifungal effect of basil leaf extract (*Ocimum sanctum* Linn.) and eugenol compared to fluconazole against *Candida* sp. isolates.

**Methods** Basil leaf extract (*Ocimum sanctum* Linn.) with doses equivalent to eugenol 800 µg/mL and 400 µg/mL, eugenol doses at 800 µg/mL and 400 µg/mL, which was then compared with fluconazole 25 µg/mL against 40 *Candida* sp. isolated stored from the oral cavity of HIV/AIDS patients.

**Results** The average inhibition zone of fluconazole was 21.81 mm, the mean inhibition zone of eugenol with doses of 800 µg/mL and 400 µg/mL were 17.07 mm and 15.89 mm, and the mean inhibition zone of basil leaf extract (*Ocimum sanctum* Linn.) with doses equivalent to eugenol 800 µg/mL and 400 µg/mL were 14.87 mm and 14.01 mm (p = 0.001 and p < 0.05).

**Conclusion** Fluconazole had a significantly higher inhibition zone against *Candida albicans* and *Candida non-albicans* isolates than basil leaf extract (*Ocimum sanctum* Linn.) and eugenol.

## Key words

Basil leaf extract (*Ocimum sanctum* Linn.), eugenol, fluconazole, antifungal susceptibility testing, oral candidiasis, HIV, AIDS.

## Introduction

Oral candidiasis is a fungal infection of the oral mucosa caused by *Candida* sp.<sup>1</sup> *Candida* sp. is a commensal fungus in healthy people, but under certain conditions it can cause an opportunistic infection. Opportunistic infections can occur as a

consequence of infection with the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS). During the course of their illness, nearly 90% of HIV/AIDS patients develop oral candidiasis.<sup>2,3</sup>

Oral candidiasis can be treated with the

antifungal drug nystatin oral suspension and/ or fluconazole as a systemic antifungal.<sup>4,5</sup> In a test of *Candida* sp. resistance to fluconazole, isolates resistant to fluconazole were found to be 48.6%. *Candida non-albicans* was the most resistant isolate, accounting for 72.2% of the total.<sup>2</sup> Antifungal drug biofilm formation and resistance are two issues that can be addressed by seeking for alternative antifungal drugs.<sup>6</sup>

Basil (*Ocimum sanctum* Linn.) is a tropical plant that can be found in abundance in Indonesia.<sup>7</sup> The main component of basil leaf (*Ocimum sanctum* Linn.) is eugenol. This compound is effective against the adaptive mechanism of *Candida albicans* biofilm resistance to fluconazole.<sup>8</sup> Based on these findings, the researchers proposed to hold an in vitro test of basil leaf extract (*Ocimum sanctum* Linn.) and eugenol against stored isolates of *Candida* sp. and compare them to standard oral candidiasis treatment fluconazole, which was now showing signs of resistance.

## Methods

The research design used in this study was an experimental laboratory with the aim of evaluating the comparison of the antifungal activity of basil leaf extract (*Ocimum sanctum* Linn.) with doses equivalent to eugenol 800 µg/mL and 400 µg/mL, eugenol at doses 800 µg/mL and 400 µg/mL was then compared with fluconazole 25 µg/mL against 40 isolates stored *Candida* sp. which consisted of 20 *Candida albicans* and 20 *Candida non-albicans* isolated

## Address for correspondence

Dwi Murtiastutik,  
Department of Dermatology and Venereology  
Faculty of Medicine, Universitas Airlangga/ Dr.  
Soetomo General Academic Teaching Hospital/  
Universitas Airlangga Teaching Hospital,  
Surabaya, Jl. Mayjen Prof. Dr. Moestopo No. 6-8  
Surabaya 60131, Indonesia.  
Ph: (031) 5501609  
Email: dwimurtiastutik@yahoo.co.id

from the oral cavity of HIV/AIDS patients who were hospitalized at the Infectious Disease Intermediate Treatment Unit (UPIPI) RSUD Dr. Soetomo Surabaya for the period April 2019 to July 2019 which was reactivated.

The antifungal activity was evaluated using the disk diffusion method with paper discs or blank discs. These data were entered into a data collection sheet and analysed with SPSS (Statistical Package for Social Sciences). This research has obtained ethical approval from the Ethics Committee of Dr. Soetomo General Academic Teaching Hospital Surabaya (0522/LOE/301.4.2/VII/2021).

## Results

In this study, using the disc diffusion method, the average results of the inhibition zone test of basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to 800 µg/mL eugenol, basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to 400 µg/mL eugenol, eugenol 800 µg/mL, and eugenol 400 µg/mL will be tested and compared with the standard antifungal treatment fluconazole against *Candida* sp.

The average fluconazole zone for all *Candida* sp. was 21.81 mm, eugenol 800 µg/mL was 17.07 mm, eugenol 400 µg/mL was 15.89 mm, basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to eugenol 800 µg/mL was 14.87 mm, and basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to eugenol 400 µg/mL was 14.01 mm. **Table 1** shows a comparison of the average inhibition zone results for all *Candida* sp.

The average fluconazole inhibition zone in *Candida albicans* species was 22.75 mm, eugenol 800 µg/mL was 16.76 mm, eugenol 400 µg/mL was 15.52 mm, basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to

**Table 1** Comparison of the mean diameter of the inhibition zone of basil leaf extract (*Ocimum sanctum* Linn.), eugenol and fluconazole in all species.

No.	Antifungal type	Number of Isolates	Average Inhibition Zone Diameter (mm)	P value
1	Fluconazole 25 µg/mL	40	21.81	0.001
2	Eugenol 800 µg/mL	40	17.07	
3	Eugenol 400 µg/mL	40	15.89	
4	Basil leaf extract equivalent to eugenol 800 µg/mL	40	14.87	
5	Basil leaf extract equivalent to eugenol 400 µg/mL	40	14.01	

**Table 2** Comparison of the mean diameter of the inhibition zone of basil leaf extract (*Ocimum sanctum* Linn.), eugenol and fluconazole in *Candida albicans*.

No.	Antifungal type	Number of Isolates	Average Inhibition Zone Diameter (mm)	P value
1	Fluconazole 25 µg/mL	40	22.75	0.001
2	Eugenol 800 µg/mL	40	16.76	
3	Eugenol 400 µg/mL	40	15.52	
4	Basil leaf extract equivalent to eugenol 800 µg/mL	40	14.41	
5	Basil leaf extract equivalent to eugenol 400 µg/mL	40	13.62	

**Table 3** Comparison of the mean diameter of the inhibition zone of basil leaf extract (*Ocimum sanctum* Linn.), eugenol and fluconazole in *Candida non-albicans*.

No.	Antifungal type	Number of Isolates	Average Inhibition Zone Diameter (mm)	P value
1	Fluconazole 25 µg/mL	40	20.86	0.001
2	Eugenol 800 µg/mL	40	17.38	
3	Eugenol 400 µg/mL	40	16.25	
4	Basil leaf extract equivalent to eugenol 800 µg/mL	40	15.34	
5	Basil leaf extract equivalent to eugenol 400 µg/mL	40	14.39	

eugenol 800 µg/mL was 14.41 mm, and basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to eugenol 400 µg/mL was 13.62 mm. **Table 2** shows a comparison of the average inhibition zone results against *Candida albicans*.

In *Candida non-albicans*, the average fluconazole inhibition zone was 20.86 mm, eugenol 800 µg/mL was 17.38 mm, eugenol 400 µg/mL was 16.25 mm, basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to eugenol 800 µg/mL was 15.34 mm, and basil leaf extract (*Ocimum sanctum* Linn.) was equivalent to eugenol 400 µg/mL was 14.39 mm. The comparison of the average inhibition zone results against *Candida non-albicans* could be observed in **Table 3**.

Because the data were not normally distributed and homogeneous, non-parametric statistical

methods (Mann Whitney Test) was used to analyze it. The results of the non-parametric statistical test showed that the data significance value was 0.001, so <0.05, which means that there was a significant difference between the mean inhibition zone of eugenol 800 µg/mL, eugenol 400 µg/mL, and basil leaf extract (*Ocimum sanctum* Linn.) equivalent to eugenol 800 µg/mL, and basil leaf extract (*Ocimum sanctum* Linn.) equivalent to eugenol 400 µg/mL compared to fluconazole which is the standard antifungal drug against the growth of *Candida* in all species, *Candida albicans* and *Candida non-albicans*.

**Discussion**

In this study, the average inhibition zone of fluconazole was greater than the average inhibition zone of eugenol and basil leaf extract

(*Ocimum sanctum* Linn.). The inhibition zones of both eugenol and basil leaf extract (*Ocimum sanctum* Linn.) are not better than fluconazole as a standard antifungal drug, but both eugenol and basil leaf extract (*Ocimum sanctum* Linn.) have antifungal effects capable of inhibiting the growth of *Candida* sp., according to the mean comparison.

In a similar study published in 2010, Ahmad and colleagues discovered that fluconazole had a better antifungal effect than eugenol, but some *Candida* sp. Have become resistant to fluconazole. Subsequently a study was conducted with combining fluconazole and eugenol which concluded that a combination of the two were superior to inhibit *Candida* sp. than fluconazole alone.<sup>9</sup> In a similar study published in 2021, Godil and colleagues discovered that basil leaf (*Ocimum sanctum* Linn.) had antifungal activity by inhibiting the growth of *Candida* sp., but in an in vitro test, the fluconazole inhibition zone was larger than that of basil (*Ocimum sanctum* Linn.) against *Candida*.<sup>10</sup>

In a study by Khan and colleagues in 2014, fluconazole revealed an MIC value of 256 µg/mL, capable of inhibiting *Candida* sp., whereas MIC of eugenol were 400µg/mL, showing that MIC of fluconazole were inferior to MIC of eugenol. This indicates that fluconazole is more sensitive in inhibiting *Candida* sp.<sup>11</sup> Basil leaf (*Ocimum sanctum* Linn.) have been shown to inhibit *Candida* sp. in previous studies, but the antifungal activity of basil leaf (*Ocimum sanctum* Linn.) is considered small due to the high MIC. Eugenol is a constituent of basil leaf (*Ocimum sanctum* Linn.) that has been shown to be effective in inhibiting *Candida* sp.<sup>9</sup>

The fluconazole inhibition zone was also significantly higher than the eugenol and basil

leaf extract (*Ocimum sanctum* Linn.) inhibition zones. Fluconazole works by inhibiting the enzyme lanosterol 14-demethylase, a microsomal cytochrome P450 enzyme found in fungal cell membranes that prevents lanosterol from being converted to ergosterol. Disturbances in these enzymes cause the integrity of the fungal membrane to be disrupted, causing fungal growth to be inhibited and thus having a fungistatic effect.<sup>4,12</sup>

In a study published in 2020 by Sharifzadeh and Shokri, it was discovered that eugenol can inhibit the growth of *Candida* sp.<sup>13</sup> Eugenol has an antifungal effect by inhibiting the biosynthesis of ergosterol, a key component of fungal cell membranes, causing damage to the membranes and a reduction in function. Damage to cell membranes disrupts the transport of nutrients (compounds and ions) through the cell membrane, preventing fungal cells from growing and resulting in cell lysis. Eugenol also contains lipophilic compounds, which can penetrate the lipid bilayer membrane, which is made up of fatty acid chains, altering the fluidity and permeability of the cell membrane, causing the cell to lose its structure and function, resulting in cell lysis.<sup>14</sup> Eugenol can also prevent the formation of pre-formed biofilms and *Candida albicans* biofilms. This substance inhibits *Candida albicans* biofilm resistance to fluconazole through an adaptive mechanism.<sup>15</sup>

In several studies investigating the antifungal effect of eugenol, the mechanism by which eugenol induces *Candida* cell death has not been fully understood. The inactivation of ergosterol synthesis and the production of free radicals, which can be an antifungal effect of eugenol, are the mechanisms of action of eugenol against *Candida*. However, the mechanism of action of eugenol is probably not related to the degradation of *Candida* fungal cell walls.<sup>15</sup> According to Jawetz and colleagues, the



mechanism by which antifungal active substances inhibit fungal growth is through membrane damage. The integrity of the cellular components will be compromised if the cell membrane is damaged, and the fungal respiration process will be disrupted. In the end, there is insufficient energy for active substance transport, causing fungal growth to be disrupted.<sup>16</sup>

The results of this study showed that by giving basil leaf extract (*Ocimum sanctum* Linn.) to both *Candida albicans* and *Candida non-albicans*, all isolates showed inhibition zones for the growth of *Candida* sp. Basil leaf (*Ocimum sanctum* Linn.) are a tropical plant that can be found throughout Indonesia. Research by De Ornay *et al.* in 2017 and Desmara *et al.* in 2017, found antifungal activity from basil leaf extract (*Ocimum sanctum* Linn.) on the in vitro growth of *Candida albicans*.<sup>7,8</sup> Eugenol is the main component of basil leaf (*Ocimum sanctum* Linn.). Several in vitro and in vivo studies show that eugenol inhibits the growth of the *Candida albicans* fungus, which causes candidiasis.<sup>17</sup>

Khan and colleagues found that basil leaf (*Ocimum sanctum* Linn.) inhibited the transition of yeast formation into hyphae, inhibited fungal proteinase enzymes, and inhibited the expression levels of HWP1, SAP1, and PLB2 genes, which are pathogenesis crucially expressed during a *Candida albicans* infection, in a study published in 2014. As a therapeutic effect of the content of basil leaf (*Ocimum sanctum* Linn.), the content of basil leaf (*Ocimum sanctum* Linn.) can cause *Candida* apoptosis by performing programmed cell death (PCD) on fungi.<sup>11</sup>

The main component of eugenol, which is highly volatile, may have caused the inhibition zone of basil leaf extract (*Ocimum sanctum* Linn.) to be inferior to fluconazole in the study.<sup>18</sup> The antifungal activity test method used can also

have an impact; in this study, the diffusion method was used to test antifungal activity, which is a common method. The diffusion method has the advantage of being a simple and quick way to see the antifungal effect by measuring the diameter of the inhibition zone formed; however, the disc diffusion method has a disadvantage in that not all substances are absorbed on the paper disc, potentially affecting the inhibition zone formed.<sup>16</sup>

The concentration of the extract, the content of antifungal compounds, the type of fungus inhibited, and the diffusion power all affect the antifungal activity of a compound. The concentration of the extract can also influence the inhibition zone formed, with the higher the concentration, the larger the clear zone. The more active compounds present, the more focused the concentration, affecting the diameter of the inhibition zone formed on fungal growth.<sup>19</sup>

Several other studies produced very encouraging results. According to Ahmad and colleagues 2010 research, eugenol is an antifungal agent with antifungal activity in vitro against *Candida albicans* and *Candida non-albicans*, that are intrinsically resistant to fluconazole. The interaction of eugenol and fluconazole was found to have a high level of synergism. In the strains that were tested, no antagonistic interactions were found. Fluconazole in combination with eugenol improves efficacy while lowering the fluconazole minimum effective dose.<sup>9</sup>

In a study conducted by Jafri and colleagues in 2020, it was discovered that administering fluconazole and eugenol to *Candida* isolated worked synergistically, with eugenol disrupting cell membrane integrity and allowing the entry of standard fluconazole drugs into mold cells. Combining antifungal drugs with eugenol has

several benefits, including increased potency, reduced drug doses, and reduced toxicity, all of which help to inhibit or overcome biofilms and antifungal drug resistance.<sup>20</sup>

Given the growing treatment failure and antifungal resistance in *Candida* sp., more in vivo studies are needed to assess the potential of these compounds for therapeutic applications and suggest ways to treat resistant *Candida* infections using a combination drug approach. The synergistic interactions between eugenol and antifungal drugs must also be evaluated, with additional studies in animal models needed to assess therapeutic efficacy, topical formulation and toxicity.<sup>9,20</sup>

## References

1. Quindós G, Gil-Alonso S, Marcos-Arias C, Sevilano E, Mateo E, Jauregizar N, dan Eraso E. Therapeutic tools for oral candidiasis: Current and new antifungal drugs. *Med Oral Patol Oral Cir Bucal.* 2019;24(2):172-80.
2. Murtiastutik D, Maharani CS, Rahmadewi R, dan Listiawan MY. Nystatin profile on *Candida* species in HIV/AIDS patients with oral candidiasis: a phenomenology study. *J Pure Appl Microbiol.* 2019;13(4):2013-19.
3. Patil S, Majumdar B, Sarode SC, Sarode GS, dan Awan KH. Oropharyngeal candidosis in HIV-Infected patients—an update. *Front Microbiol.* 2018;1(1):1-9.
4. Kundu RV, dan Garg A. 2012. 'Yeast Infections: Candidiasis, tinea (pityriasis) versicolor, and malassezia (pityrosporum) folliculitis'. In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Lefell DJ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. 8th ed. New York: McGraw Hill. 2298-301.
5. Lydiawati E, Listiawan MY, Murtiastutik D, Rahmadewi R, Prakoeswa CRS, Avanti C, Fitriani E, Astha ET, Astari L, dan Zulkarnain I. In vitro antifungal susceptibility testing of tea tree oil (TTO) 5% compared with nystatin against *Candida* sp. as important agent of oral candidiasis in HIV/AIDS patients. *BIKKK.* 2020;32(3):189-94.
6. Rauseo AM, Coler-Reilly A, Larson L, dan Spec A. Hope on the horizon: novel fungal treatments in development. *Open Forum Infect Dis.* 2020;7(2):5-23.
7. Desmara S, Rezeki S, dan Sunnati S. Konsentrasi hambat minimum dan konsentrasi bunuh minimum ekstrak daun kemangi (*O. sanctum* L.) terhadap pertumbuhan *Candida albicans*. *J Caninus Denst.* 2017;2(1):31-9.
8. De Ornay AK, Prehananto H, dan Dewi ASS. Growth inhibition of *Candida albicans* and power kill *Candida albicans* extract basil leave. *Jurnal Wiyata.* 2017;4(1):78-83.
9. Ahmad A, Khan A, dan Yousuf S. Proton translocating ATPase mediated fungicidal activity of eugenol and thymol. *Fitoterapia.* 2010;81(1):157-62.
10. Godil AZ, Bhagat D, Das P, Kazi AI, Dugal R, dan Satpute S. Fluconazole and *Ocimum sanctum* Oil in soft denture liners to treat biofilms of *Candida albicans* associated with denture stomatitis. *Dentistry.* 2021;9(1):1-11.
11. Khan A, Ahmad A, Khan LA, dan Manzoor N. *Ocimum sanctum* (L.) essential oil and its lead molecules induce apoptosis in *Candida albicans*. *Res Microbiol.* 2014;165(6):411-9.
12. Ghannoum M, Salem I, dan Christensen L. 2019. 'Antifungals'. In: Kang, S., Amagai, M., Bruckner, A.L., Enk, A.H., Margolis, D.J., McMichael, A.J., Orringer, J.S., editors. Fitzpatrick's dermatology. 9th ed. New York: McGraw Hill, 3436-45.
13. Sharifzadeh A, dan Shokri H. In vitro synergy of eugenol on the antifungal effects of voriconazole against *Candida tropicalis* and *Candida krusei* strains isolated from the genital tract of mares. *Equine Vet J.* 2020;3(1):94-101.
14. Brajawikalpa RS. dan Ramzy AN. Uji efektivitas antijamur minyak atsiri daun cengkeh (*Syzygium aromaticum* L.) terhadap pertumbuhan *Malassezia furfur*. *Jurnal Kedokteran dan Kesehatan.* 2018;4(1):49-51.
15. Silva ICG, Santos HBP, Cavalcanti YW, Nonaka CFW, Sousa SA, dan Castro RD. Antifungal activity of eugenol and its association with nystatin on *Candida albicans*. *Pesquisa Brasileira em Odontopediatria e Clínica Integrada.* 2017;17(1):1-8.
16. Jawetz, Melnick, dan Adelberg. 2007. 'Mikrobiologi Kedokteran'. 23rd ed. Jakarta: ISBN 978-979-448-859-1. 273-5.

17. Núñez IC, Arranz JC, Rivas CB, Mendonça PM, Perez K, Sánchez CD, Cortinhas LB, Silva CF, Carvalho M, dan Queiroz M. Chemical composition and toxicity of *O. sanctum* L. var. *cubensis* essential oil up-growing in the Eastern of Cuba. *Phytopathology*. 2017;**9**(7):1021-8.
18. De Paula SB, Bartelli TF, Di Raimo V, Santos JP, Morey AT, Bosini MA, Nakamura CV, Yamauchi LM, Yamada-Ogatta SF. Effect of eugenol on cell surface hydrophobicity, adhesion, and biofilm of *Candida tropicalis* and *Candida dubliniensis* isolated from oral cavity of HIV-Infected patients. *Evid Based Complement Alternat Med*. 2014;**1**(1):1-8.
19. Andayani A, Susilowati A, dan Pangastuti A. AntiCandida minyak atsiri lengkuas putih (*Alpinia galanga*) terhadap *Candida albicans* penyebab candidiasis secara invitro. *El Vivo*. 2014;**2**(2):1-9.
20. Jafri H, Banerjee G, dan Khan MSA. Synergistic interaction of eugenol and antimicrobial drugs in eradication of single and mixed biofilms of *Candida albicans* and *Streptococcus mutans*. *AMB Expr*. 2020;**1**(10):185.